Prognostic Efficacy of the Albumin Grade in Patients with Hepatocellular Carcinoma
Yuichi Hirano,Kazuhiro Nouso,Kazuya Kariyama,Atsushi Hiraoka,Shohei Shiota,Akiko Wakuta,Satoshi Yasuda,Hidenori Toyoda,Kunihiko Tsuji,Takeshi Hatanaka,Satoru Kakizaki,Atsushi Naganuma,Toshifumi Tada,Ei Itobayashi,Toru Ishikawa,Noritomo Shimada,Koichi Takaguchi,Akemi Tsutsui,Takuya Nagano,Michitaka Imai,Shinichiro Nakamura,Takashi Kumada,Real-Life Practice Experts for HCC (RELPEC) Study Group in Japan
DOI: https://doi.org/10.18926/AMO/67662
Abstract:We previously found that "albumin grade", formerly called the "ALBS grade," demonstrated significant capability for prognostic stratification in hepatocellular carcinoma (HCC) patients treated with lenvatinib. The purpose of the present study was to compare the performance of the albumin grade with that of the modified albumin-bilirubin (mALBI) grade in predicting overall survival of HCC patients with different BCLC stages and treatment types. We enrolled 7,645 Japanese patients newly diagnosed with HCC using the Akaike information criteria (AIC), likelihood ratio, and C-index in different Barcelona Clinic Liver Cancer (BCLC) stages and treatments. The albumin grade showed similar and slightly better performance than the mALBI grade for BCLC stage 0 and A and especially for patients who underwent curative surgery and ablation. In patients treated with transcatheter arterial chemoembolization, molecular targeted agents, and the best supportive care, the mALBI grade had better performance than the albumin grade. However, the differences of the indices were very small in all scenarios. Overall, the albumin grade was comparable in efficacy to the mALBI grade, showing particular benefit for patients with early-stage HCC.